DIRS.INFO The most relevant business & tech news

☆ Eli Lilly climbs on win for rival weight-loss drug, and we still feel good about Abbott Labs
▼ + stars: | 2024-03-28 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Abbott update : Shares of Abbott Laboratories were slightly higher Thursday, on pace for their third straight day of gains. The embattled cosmetics company was the top-performing Club stock in Thursday's session, boosted by an upgrade at Bank of America . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Wegovy, Abbott, Louis, Jim, Reckitt's Mead Johnson, Mead, Johnson, Stanley Black, Decker, Estee Lauder, Lauder, there's, Jim Cramer's, AJ Mast Organizations: CNBC, Stocks, Bloomberg, Amazon Pharmacy, Rite, Abbott Laboratories, Abbott, NEC, Home, U.S, Bank of America, Jim Cramer's Charitable, Getty Locations: U.S, St, Illinois, China, Indianapolis , Indiana

☆ Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
▼ + stars: | 2024-03-16 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. The spokesperson added that state Medicaid programs would be required to cover Wegovy for its new cardiovascular use. But Gremminger said the standard of care for the long-term use of weight loss drugs is "in flux." State employees will no longer have insurance coverage for GLP-1s when used for weight loss at the beginning of next month. Both drugmakers have launched programs to help patients, with or without commercial insurance coverage, afford their weight loss treatments.

Persons: Klesty, John Crable, Wegovy, Jaime Almandoz, Joe Buglewicz, Shawn Gremminger, Hartley, Gremminger, Dale Folwell, We've, Folwell, Phelan M, Eli Lilly, Ceci Connolly, Julie Stich Organizations: Reuters, Novo Nordisk, CNBC, Medicare, Services, FDA, CVS, Aetna, International Foundation of Employee, Drug Administration, University of Texas Southwestern Medical Center, Washington Post, Getty, National Alliance of Healthcare, Taft, Nordisk, Nordisk's Ozempic, GOP, Carolina, Republican Governors Association, AP, Alliance of Community Health, U.S . Health, IFEBP, BMI Locations: U.S, Novo, Dallas, North Carolina, Orlando , Florida

☆ Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. GLP-1 drugs encourage the production of hormones that cause weight loss through reduced appetite. Nevertheless, Berenberg's analysts believe the bigger, underappreciated, near-term opportunity lies with companies preparing to launch generic versions of the first-generation GLP-1 drugs. Under-the-radar picks Sartorius and SKAN Group, Berenberg's "under-the-radar" pick, are also expected to benefit from manufacturing generic GLP-1 drugs. The investment bank sees Sartorius benefiting from the growing commercialization of GLP-1 drugs and forecasts shares to rise by 27% over the next 12 months.

Persons: Eli Lilly, Novo, Sandoz, Berenberg Organizations: Novo Nordisk, —, Nordisk, Novo Nordisk's Victoza, SKAN Locations: Germany, Europe, Sandoz, United States

☆ These are the top 4 Club stocks — and the bottom 4 — during the third quarter
▼ + stars: | 2023-09-30 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +11 min

Here's a look at the top four and bottom four Club stocks in the third quarter as Wall Street gears up for the first trading day of the fourth quarter on Monday. The winners LLY mountain 2023-06-30 Eli Lilly's stock performance in the third quarter. CAT mountain 2023-06-30 Caterpillar's stock performance in the third quarter. F mountain 2023-06-30 Ford Motor's stock performance since the end of the second quarter. In the first few weeks of the quarter, shares of the medical equipment giant actually edged higher, but its fortunes would turn significantly.

Persons: —, Eli Lilly, Eli Lilly's, Lilly, Wegovy —, Microsoft's, Locker, Mary, Jim Cramer, Dillon, Estee Lauder, we're, Fabrizio Freda, Stellantis, Ford, Jim, we've, there's, Foot Locker, GE Healthcare's, Jim Cramer's, Frederick Florin Organizations: Federal Reserve, Dow Jones, Nasdaq, Dow, Novo Nordisk, Investors, Caterpillar, Natural Resources, West Texas, Google, Microsoft, FL, Ford, United Auto Workers, UAW, General Motors, Detroit, GM, GE, GE Healthcare, CNBC, AFP, Getty Locations: U.S, WTI, Asia, Illinois, Estee Lauder, GOOGL, Fegersheim, France

☆ How soaring demand for Ozempic and Wegovy is altering Denmark’s economy
▼ + stars: | 2023-08-21 | by ( Anna Cooban | ) edition.cnn.com time to read: +3 min

Its maker, Novo Nordisk (NONOF), has raked in almost 49 billion Danish krone in profit ($7 billion) over the first six months of this year, up 32% from the same period in 2022. Novo Nordisk also produces Ozempic, a drug developed to treat type 2 diabetes but which contains the same active ingredient as Wegovy. Surging demandShares in Novo Nordisk have soared 34% since the start of 2023 to give the company a market capitalization of 2.2 trillion Danish krone ($322 billion). The stock shot up earlier this month after Novo Nordisk published the results of a five-year trial on the impact of Wegovy on cardiovascular disease. Novo Nordisk now expects its profits to grow by up to 37% this year, much higher growth than the maximum 19% rise it forecast in February.

Persons: Jens Naervig Pedersen, Pedersen, Jaap Arriens, ” Pedersen, “ We’ve, Andrew Kenningham, “, juggernauts Roche Organizations: London CNN, Nordic, Novo Nordisk, Danish, Danske Bank, European Central Bank, CNN, Capital Economics, AstraZeneca, Kaiser Family Foundation Locations: United States, Denmark, Danish, Europe

☆ WeightWatchers could either win big or lose faithful customers, or both, in its pivot to Ozempic trend
▼ + stars: | 2023-07-22 | by ( Jordan Hart | ) www.businessinsider.com time to read: +3 min

Sequence offers access to weight-loss drugs like Ozempic and Wegovy. Analysts say the move could save the company, but some WeightWatchers members aren't happy. Although the medication has gained popularity online and among celebrities, veteran WeightWatchers members aren't all happy with the company's pivot. Some WeightWatchers members expressed concern that the company was abandoning its message of self-restraint for the easy solution of weight-loss medication. Sequence, meanwhile, prescribes weight-loss medications like Ozempic and Wegovy and helps patients afford the drugs through insurance and reimbursements.

Persons: WeightWatchers, aren't, They're, Goldman Sachs, Sima Sistani, Jenny Craig Organizations: WW, Inc, Bloomberg, Employers

☆ Medicare is barred from paying for weight-loss drugs like Wegovy. Lawmakers just took the first step to change that.
▼ + stars: | 2023-07-20 | by ( ) www.businessinsider.com time to read: +5 min

Medicare is barred under a 2003 law from paying for weight-loss medications like Wegovy. Lawmakers on Thursday reintroduced a bill that would expand Medicare coverage to the drugs. A major roadblock has long stood in the way of older Americans getting treatments for obesity: Medicare. But US lawmakers on Thursday took steps to broaden access to weight-loss treatment for seniors. Medicare coverage might prod other health insurers to pay for weight-loss medications, as private health plans tend to follow Medicare's lead.

Persons: Democratic Sen, Tom Carper, Carper, Republican Sen, Bill Cassidy, Raul Ruiz, Brad Wenstrup, Eli Lilly's Mounjaro, Wegovy, Eli Lilly, clamor, Chris Gallagher Organizations: Medicare, Democratic, Republican, California Democrat, Lawmakers, Nordisk's Wegovy, Vanderbilt University, Novo Nordisk, Wall Street Journal, Obesity, Coalition Locations: California, Ohio

☆ The Risks of Taking Drugs Like Ozempic When You’re Over 65
▼ + stars: | 2023-07-17 | by ( Dani Blum | More About Dani Blum | ) www.nytimes.com time to read: +1 min

That’s particularly a concern for older adults, obesity medicine experts say. The more muscle someone over the age of 65 loses, the greater their risk of becoming frail or suffering a fracture or fall (which can be fatal in older adults). It is crucial for older adults to maintain muscle mass so that they can stay mobile and independent. Muscle mass naturally dwindles with age. Clinical trials on semaglutide, the active ingredient in Ozempic and Wegovy, have typically enrolled people in their 40s and 50s.

Persons: — you’re, Scott Hagan, Janice Jin Hwang Organizations: University of Washington, University of North Carolina School of Medicine

☆ People probably have to be on Ozempic forever. But no one is ready for the bill.
▼ + stars: | 2023-06-02 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +9 min

But she knows — from experience — that probably won't be possible if she has to stop taking the drug once her manufacturer-issued coupons expire. But the injections don't work once people stop taking them. Li Ran/Xinhua via Getty ImagesMany health insurers and employers have long declined to pay for weight-loss drugs. He has resumed taking weight-loss medication but said he hoped to go down to a lower dose. Want to tell us about your experience with health insurance and weight-loss drugs?

Persons: Tara Rothenhoefer, Rothenhoefer, Eli Lilly's, Insider's Gabby Landsverk, —, Wegovy, Rothenhoefer Novo, we're, Dr, Martin Lange, Novo, Eli Lilly, Li Ran, Sean Duffy, Omada, Duffy, hungrier, Nisha Patel, it's, " Lange, Bill, Gabby Landsverk, Shelby Livingston, Hilary Brueck Organizations: Rothenhoefer Novo Nordisk, Novo Nordisk, Getty, National Library of Medicine Locations: San Francisco, Novo, Xinhua, slivingston

☆ Why buzzy weight-loss drugs such as Ozempic and Wegovy cost so much more in the US
▼ + stars: | 2023-05-10 | by ( ) www.businessinsider.com time to read: +4 min

Trendy weight-loss drugs cost much more in the US than in other countries. The price of semaglutide, the drug sold as Wegovy, was three times higher in the US than in the UK. If you're searching for affordable weight-loss drugs, you may be better off looking outside of the US. New weight-loss drugs are unaffordableGetty ImagesWegovy and Ozempic are part of a class of weight-loss drugs known as GLP-1 agonists that have soared in popularity in recent months. Drug prices are highest in the USThe variation in prices for weight-loss drugs across the world is striking.

☆ A flurry of news outside the portfolio has implications for 3 of our stocks
▼ + stars: | 2023-04-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Here are three noteworthy news developments over the past two days, which contain useful insights about our stocks. For the full year 2023, Novo now expects sales growth in the range of 24% and 30%, compared to prior estimates of 13% to 19%. In addition, operating profit growth is expected to be in the range of 28% and 34%, up from a prior range of 13% to 19%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ The 13 startups to watch in the $100 billion market for buzzy new weight-loss drugs like Ozempic
▼ + stars: | 2023-04-11 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +3 min

Healthcare startups are launching to prescribe weight-loss drugs such as Ozempic. They're chasing what's projected to be a $100 billion market for the drugs. Venture-backed health startups are vying for a piece of the booming market for new prescription drugs designed to help with weight loss. Many startups offering weight-loss drugs have flooded social media platforms with ads for the shots. Insider rounded up 13 venture-backed startups competing for customers in the lucrative GLP-1 weight-loss market, listed from least to most funding raised.

☆ 13 startups vying for a slice of the $100 billion market for buzzy new weight-loss drugs
▼ + stars: | 2023-04-05 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +3 min

They have soared in popularity over the last year, in part from social media attention and billionaires like Elon Musk touting the drugs’ weight loss effects. Ozempic is not approved for weight loss, but doctors sometimes prescribe it off-label for that purpose. Harper took Ozempic off-label for weight loss from May until November (she paused while moving to Washington state but plans to start again). For Yazeed, weight loss was not the reason she went on Ozempic, nor was it a goal. He hasn't experienced side effects or weight loss from Ozempic, he said, but he recognizes that isn't true for everyone.

☆ New guidelines for treating childhood obesity include medications and surgery for first time
▼ + stars: | 2023-01-09 | by ( Kaitlin Sullivan | Kaitlin Sullivan Is A Contributor For Nbcnews.Com Who Has Worked With Nbc News Investigations. She Reports On Health | Science | ) www.nbcnews.com time to read: +8 min

Intensive behavioral and lifestyle changes should be the first-line approach, but the AAP also includes recommendations for anti-obesity medications and surgery for the first time. The guidelines say that pediatricians should offer weight-loss drugs for children age 12 and up with obesity. She also acknowledged that these lifestyle changes can be really hard to adopt, especially for overworked and low-income parents. The more adverse the environment around you, the harder it is to live a healthy lifestyle,” Hassink said. Medications and surgery are expensive, and asking overstretched parents to implement lifestyle changes is not always realistic.

Search resuls for: "Wegovy —"

15 mentions found